2 results
Approved WMOCompleted
Phase 1b:Primary:- To evaluate the safety and tolerability and determine the recommended Phase 2 dose (RP2D) and schedule of ALRN-6924 when administered to patients with TP53-mutated extensive disease (ED) small cell lung cancer (SCLC) receiving…
Approved WMOCompleted
The objective of the present study is to evaluate the safety of Womed Leaf after hysteroscopic myomectomy and its potential efficacy in preventing IUA at second look hysteroscopy.